<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14932">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00240500</url>
  </required_header>
  <id_info>
    <org_study_id>100448</org_study_id>
    <nct_id>NCT00240500</nct_id>
  </id_info>
  <brief_title>Follow-up Study 16-20 Years After Primary Vaccination Against Hepatitis B of Newborns From HBeAg+ &amp; HBsAg+ Mothers</brief_title>
  <official_title>Long-Term F-U Study at Yrs 16-20, to Evaluate the Persistence of Immune Response of GSK Biologicals' Hepatitis B Vaccine in Newborns of HBeAg+ and HBsAg+ Mothers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Thailand: Ministry of Public Health</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the persistence of anti-hepatitis B surface antigen
      (anti-HBs) antibodies 16, 17, 18, 19 and 20 years after administration of the first dose of
      the study vaccine. The Protocol Posting has been updated in order to comply with the FDA
      Amendment Act, Sep 2007.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary study was designed to evaluate the immunogenicity and protective efficacy of
      hepatitis B vaccine in newborns of HBeAg+ and HBsAg+ mothers in comparison with a historical
      control group.

      The present study is carried out to evaluate the anti-HBs persistence 16-20 years after the
      first vaccine dose and to further investigate the prevalence and incidence of other
      hepatitis B markers and the clinical significance of these at all time points from Year
      16-20.

      No additional subjects will be recruited during this long-term follow-up study and no
      vaccine will be administered.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Anti-Hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations</measure>
    <time_frame>Years 17, 18, 19 and 20.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of Serological Markers for Hepatitis B Infection</measure>
    <time_frame>Years 17, 18, 19 and 20.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Review for Hepatitis B Infection Status</measure>
    <time_frame>Over the entire 4 year follow up period (17 - 20 years)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">109</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>HBV-5 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>neonates born to HBsAg- and HBeAg- mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HBV-6 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>neonates born to HBsAg- and HBeAg- mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HBV-3 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>neonates born to HBsAg+ and HBeAg- mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HBV-4 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>neonates born to HBsAg+ and HBeAg- mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HBV-2 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>neonates born to HBsAg+ and HBeAg+ mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HBV-1 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>neonates born to HBsAg+ and HBeAg+ mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Engerixâ„¢-B</intervention_name>
    <description>In the primary study, subjects received HBV (10 milligram) vaccine according to a 0, 1 and 2 month schedule with a booster dose at Month 12. Subjects in the 5-dose vaccination regimen received a booster dose of HBV vaccine at Month 60.</description>
    <arm_group_label>HBV-1 Group</arm_group_label>
    <arm_group_label>HBV-2 Group</arm_group_label>
    <arm_group_label>HBV-3 Group</arm_group_label>
    <arm_group_label>HBV-4 Group</arm_group_label>
    <arm_group_label>HBV-5 Group</arm_group_label>
    <arm_group_label>HBV-6 Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who had received at least one dose of the study vaccine in the primary study
             (103860/064)

          -  Written informed consent obtained from each subject before each blood sampling visit
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <lastchanged_date>May 28, 2009</lastchanged_date>
  <firstreceived_date>October 13, 2005</firstreceived_date>
  <firstreceived_results_date>October 30, 2008</firstreceived_results_date>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>GSK</organization>
  </responsible_party>
  <keyword>Long-term follow-up</keyword>
  <keyword>Hepatitis B antibody persistence</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>HBV 5 Group</title>
          <description>neonates born to Hepatitis B surface antigen negative (HBsAg-) and Hepatitis B e antigen negative (HBeAg-) mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)</description>
        </group>
        <group group_id="P2">
          <title>HBV 2 Group</title>
          <description>neonates born to Hepatitis B surface antigen positive (HBsAg+) and Hepatitis B e antigen positive (HBeAg+) mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)</description>
        </group>
        <group group_id="P3">
          <title>HBV 1 Group</title>
          <description>neonates born to HBsAg+ and HBeAg+ mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)</description>
        </group>
        <group group_id="P4">
          <title>HBV 4 Group</title>
          <description>neonates born to HBsAg+ and HBeAg- mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)</description>
        </group>
        <group group_id="P5">
          <title>HBV 3 Group</title>
          <description>neonates born to HBsAg+ and HBeAg- mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)</description>
        </group>
        <group group_id="P6">
          <title>HBV 6 Group</title>
          <description>neonates born to HBsAg- and HBeAg- mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="23"/>
                <participants group_id="P5" count="29"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="26"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HBV 5 Group</title>
          <description>neonates born to Hepatitis B surface antigen negative (HBsAg-) and Hepatitis B e antigen negative (HBeAg-) mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)</description>
        </group>
        <group group_id="B2">
          <title>HBV 2 Group</title>
          <description>neonates born to Hepatitis B surface antigen positive (HBsAg+) and Hepatitis B e antigen positive (HBeAg+) mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)</description>
        </group>
        <group group_id="B3">
          <title>HBV 1 Group</title>
          <description>neonates born to HBsAg+ and HBeAg+ mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)</description>
        </group>
        <group group_id="B4">
          <title>HBV 4 Group</title>
          <description>neonates born to HBsAg+ and HBeAg- mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)</description>
        </group>
        <group group_id="B5">
          <title>HBV 3 Group</title>
          <description>neonates born to HBsAg+ and HBeAg- mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)</description>
        </group>
        <group group_id="B6">
          <title>HBV 6 Group</title>
          <description>neonates born to HBsAg- and HBeAg- mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="17"/>
                <measurement group_id="B4" value="23"/>
                <measurement group_id="B5" value="29"/>
                <measurement group_id="B6" value="3"/>
                <measurement group_id="B7" value="109"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="16.5" spread="0.51"/>
                <measurement group_id="B2" value="16.6" spread="0.5"/>
                <measurement group_id="B3" value="16.5" spread="0.51"/>
                <measurement group_id="B4" value="16.4" spread="0.51"/>
                <measurement group_id="B5" value="16.8" spread="0.44"/>
                <measurement group_id="B6" value="16.7" spread="0.58"/>
                <measurement group_id="B7" value="16.6" spread="0.50"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="9"/>
                <measurement group_id="B3" value="11"/>
                <measurement group_id="B4" value="7"/>
                <measurement group_id="B5" value="18"/>
                <measurement group_id="B6" value="1"/>
                <measurement group_id="B7" value="53"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="11"/>
                <measurement group_id="B3" value="6"/>
                <measurement group_id="B4" value="16"/>
                <measurement group_id="B5" value="11"/>
                <measurement group_id="B6" value="2"/>
                <measurement group_id="B7" value="56"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations</title>
        <description>During this follow-up study, it was planned to collect data from Year 16 through to Year 20 after primary vaccination. By the time the study protocol was approved, it was too late to collect data on Year 16. Therefore, the table presents mean concentrations expressed in milli-international units/milliliter (mIU/mL) at years 17, 18, 19 and 20.</description>
        <time_frame>Years 17, 18, 19 and 20.</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>HBV 5 Group</title>
            <description>neonates born to Hepatitis B surface antigen negative (HBsAg-) and Hepatitis B e antigen negative (HBeAg-) mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)</description>
          </group>
          <group group_id="O2">
            <title>HBV 2 Group</title>
            <description>neonates born to Hepatitis B surface antigen positive (HBsAg+) and Hepatitis B e antigen positive (HBeAg+) mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)</description>
          </group>
          <group group_id="O3">
            <title>HBV 1 Group</title>
            <description>neonates born to HBsAg+ and HBeAg+ mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)</description>
          </group>
          <group group_id="O4">
            <title>HBV 4 Group</title>
            <description>neonates born to HBsAg+ and HBeAg- mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)</description>
          </group>
          <group group_id="O5">
            <title>HBV 3 Group</title>
            <description>neonates born to HBsAg+ and HBeAg- mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)</description>
          </group>
          <group group_id="O6">
            <title>HBV 6 Group</title>
            <description>neonates born to HBsAg- and HBeAg- mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="20"/>
                  <measurement group_id="O3" value="17"/>
                  <measurement group_id="O4" value="23"/>
                  <measurement group_id="O5" value="29"/>
                  <measurement group_id="O6" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations</title>
            <description>During this follow-up study, it was planned to collect data from Year 16 through to Year 20 after primary vaccination. By the time the study protocol was approved, it was too late to collect data on Year 16. Therefore, the table presents mean concentrations expressed in milli-international units/milliliter (mIU/mL) at years 17, 18, 19 and 20.</description>
            <units>mIU/mL</units>
            <param>Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Year 17</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="87.6" lower_limit="27.6" upper_limit="278.2"/>
                  <measurement group_id="O2" value="43.8" lower_limit="22.0" upper_limit="87.4"/>
                  <measurement group_id="O3" value="143.4" lower_limit="39.2" upper_limit="523.9"/>
                  <measurement group_id="O4" value="34.4" lower_limit="12.3" upper_limit="95.8"/>
                  <measurement group_id="O5" value="90.9" lower_limit="45.8" upper_limit="180.3"/>
                  <measurement group_id="O6" value="10.6" lower_limit="0.4" upper_limit="251.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 18</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="96.2" lower_limit="37.8" upper_limit="244.8"/>
                  <measurement group_id="O2" value="63.9" lower_limit="32.2" upper_limit="126.6"/>
                  <measurement group_id="O3" value="121.6" lower_limit="31.8" upper_limit="465.0"/>
                  <measurement group_id="O4" value="33.1" lower_limit="15.2" upper_limit="72.2"/>
                  <measurement group_id="O5" value="89.1" lower_limit="43.8" upper_limit="181.3"/>
                  <measurement group_id="O6" value="19.2" lower_limit="0.0" upper_limit="2615400000"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 19</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="37.4" lower_limit="14.8" upper_limit="94.4"/>
                  <measurement group_id="O2" value="34.5" lower_limit="20.6" upper_limit="57.7"/>
                  <measurement group_id="O3" value="108.1" lower_limit="30.6" upper_limit="382.8"/>
                  <measurement group_id="O4" value="22.5" lower_limit="11.7" upper_limit="43.6"/>
                  <measurement group_id="O5" value="62.1" lower_limit="30.7" upper_limit="125.6"/>
                  <measurement group_id="O6" value="26.9" lower_limit="2.0" upper_limit="363.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 20</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="46.4" lower_limit="19.6" upper_limit="109.8"/>
                  <measurement group_id="O2" value="25.8" lower_limit="14.4" upper_limit="46.3"/>
                  <measurement group_id="O3" value="101.8" lower_limit="28.7" upper_limit="361.7"/>
                  <measurement group_id="O4" value="20.3" lower_limit="10.2" upper_limit="40.6"/>
                  <measurement group_id="O5" value="55.5" lower_limit="30.1" upper_limit="102.1"/>
                  <measurement group_id="O6" value="12.8" lower_limit="0.0" upper_limit="7642461"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Prevalence of Serological Markers for Hepatitis B Infection</title>
        <description>It was initially planned to collect data from Year 16 through to Year 20 after primary vaccination. By the time the study protocol was approved, it was too late to collect data on Year 16. Only the subjects positive for HBsAg or anti Hepatitis B core antigen (anti-HBc) were tested for HBeAg &amp; anti-HBe</description>
        <time_frame>Years 17, 18, 19 and 20.</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>HBV 5 Group</title>
            <description>neonates born to Hepatitis B surface antigen negative (HBsAg-) and Hepatitis B e antigen negative (HBeAg-) mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)</description>
          </group>
          <group group_id="O2">
            <title>HBV 2 Group</title>
            <description>neonates born to Hepatitis B surface antigen positive (HBsAg+) and Hepatitis B e antigen positive (HBeAg+) mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)</description>
          </group>
          <group group_id="O3">
            <title>HBV 1 Group</title>
            <description>neonates born to HBsAg+ and HBeAg+ mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)</description>
          </group>
          <group group_id="O4">
            <title>HBV 4 Group</title>
            <description>neonates born to HBsAg+ and HBeAg- mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)</description>
          </group>
          <group group_id="O5">
            <title>HBV 3 Group</title>
            <description>neonates born to HBsAg+ and HBeAg- mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)</description>
          </group>
          <group group_id="O6">
            <title>HBV 6 Group</title>
            <description>neonates born to HBsAg- and HBeAg- mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="20"/>
                  <measurement group_id="O3" value="17"/>
                  <measurement group_id="O4" value="23"/>
                  <measurement group_id="O5" value="29"/>
                  <measurement group_id="O6" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Prevalence of Serological Markers for Hepatitis B Infection</title>
            <description>It was initially planned to collect data from Year 16 through to Year 20 after primary vaccination. By the time the study protocol was approved, it was too late to collect data on Year 16. Only the subjects positive for HBsAg or anti Hepatitis B core antigen (anti-HBc) were tested for HBeAg &amp; anti-HBe</description>
            <units>Percentage of participants (%)</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Year 17, HBsAg Negative</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                  <measurement group_id="O2" value="93.7"/>
                  <measurement group_id="O3" value="100"/>
                  <measurement group_id="O4" value="100"/>
                  <measurement group_id="O5" value="96.3"/>
                  <measurement group_id="O6" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 17, HBsAg Positive</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="6.3"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="3.7"/>
                  <measurement group_id="O6" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 17, Anti HBc Negative</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                  <measurement group_id="O2" value="68.7"/>
                  <measurement group_id="O3" value="78.6"/>
                  <measurement group_id="O4" value="100"/>
                  <measurement group_id="O5" value="100"/>
                  <measurement group_id="O6" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 17, Anti HBc Positive</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="31.3"/>
                  <measurement group_id="O3" value="21.4"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 17, HBeAg Negative</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="100"/>
                  <measurement group_id="O3" value="100"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="100"/>
                  <measurement group_id="O6" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 17, HBeAg Positive</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 17, Anti HBeAg Negative</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="80"/>
                  <measurement group_id="O3" value="100"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="100"/>
                  <measurement group_id="O6" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 17, Anti HBeAg Positive</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="20"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 18, HBsAg Negative</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                  <measurement group_id="O2" value="100"/>
                  <measurement group_id="O3" value="100"/>
                  <measurement group_id="O4" value="100"/>
                  <measurement group_id="O5" value="96.4"/>
                  <measurement group_id="O6" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 18, HBsAg Positive</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="3.6"/>
                  <measurement group_id="O6" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 18, Anti HBc Negative</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="94.1"/>
                  <measurement group_id="O2" value="75"/>
                  <measurement group_id="O3" value="71.4"/>
                  <measurement group_id="O4" value="100"/>
                  <measurement group_id="O5" value="100"/>
                  <measurement group_id="O6" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 18, Anti HBc Positive</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.9"/>
                  <measurement group_id="O2" value="25"/>
                  <measurement group_id="O3" value="28.6"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 18, HBeAg Negative</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                  <measurement group_id="O2" value="100"/>
                  <measurement group_id="O3" value="100"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="100"/>
                  <measurement group_id="O6" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 18, HBeAg Positive</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 18, Anti HBeAg Negative</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                  <measurement group_id="O2" value="100"/>
                  <measurement group_id="O3" value="100"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="100"/>
                  <measurement group_id="O6" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 18, Anti HBeAg Positive</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 19, HBsAg Negative</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="92.9"/>
                  <measurement group_id="O2" value="94.1"/>
                  <measurement group_id="O3" value="100"/>
                  <measurement group_id="O4" value="85"/>
                  <measurement group_id="O5" value="82.1"/>
                  <measurement group_id="O6" value="75"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 19, HBsAg Positive</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.1"/>
                  <measurement group_id="O2" value="5.9"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="15"/>
                  <measurement group_id="O5" value="17.9"/>
                  <measurement group_id="O6" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 19, Anti HBc Negative</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                  <measurement group_id="O2" value="76.5"/>
                  <measurement group_id="O3" value="78.6"/>
                  <measurement group_id="O4" value="95"/>
                  <measurement group_id="O5" value="100"/>
                  <measurement group_id="O6" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 19, Anti HBc Positive</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="23.5"/>
                  <measurement group_id="O3" value="21.4"/>
                  <measurement group_id="O4" value="5"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 19, HBeAg Negative</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                  <measurement group_id="O2" value="100"/>
                  <measurement group_id="O3" value="100"/>
                  <measurement group_id="O4" value="100"/>
                  <measurement group_id="O5" value="80"/>
                  <measurement group_id="O6" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 19, HBeAg Positive</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="20"/>
                  <measurement group_id="O6" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 19, Anti HBeAg Negative</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                  <measurement group_id="O2" value="100"/>
                  <measurement group_id="O3" value="100"/>
                  <measurement group_id="O4" value="100"/>
                  <measurement group_id="O5" value="100"/>
                  <measurement group_id="O6" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 19, Anti HBeAg Positive</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 20, HBsAg Negative</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                  <measurement group_id="O2" value="76.5"/>
                  <measurement group_id="O3" value="92.9"/>
                  <measurement group_id="O4" value="78.9"/>
                  <measurement group_id="O5" value="84.6"/>
                  <measurement group_id="O6" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 20, HBsAg Positive</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="23.5"/>
                  <measurement group_id="O3" value="7.1"/>
                  <measurement group_id="O4" value="21.1"/>
                  <measurement group_id="O5" value="15.4"/>
                  <measurement group_id="O6" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 20, Anti HBc Negative</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="93.7"/>
                  <measurement group_id="O2" value="76.5"/>
                  <measurement group_id="O3" value="78.6"/>
                  <measurement group_id="O4" value="100"/>
                  <measurement group_id="O5" value="100"/>
                  <measurement group_id="O6" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 20, Anti HBc Positive</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.3"/>
                  <measurement group_id="O2" value="23.5"/>
                  <measurement group_id="O3" value="21.4"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 20, HBeAg Negative</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                  <measurement group_id="O2" value="100"/>
                  <measurement group_id="O3" value="100"/>
                  <measurement group_id="O4" value="100"/>
                  <measurement group_id="O5" value="100"/>
                  <measurement group_id="O6" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 20, HBeAg Positive</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 20, Anti HBeAg Negative</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                  <measurement group_id="O2" value="100"/>
                  <measurement group_id="O3" value="100"/>
                  <measurement group_id="O4" value="100"/>
                  <measurement group_id="O5" value="100"/>
                  <measurement group_id="O6" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Year 20, Anti HBeAg Positive</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Review for Hepatitis B Infection Status</title>
        <description>Chronic hepatitis B (HB) carrier is defined as positive for anti-HBc AND HBsAg at two or more consecutive time points</description>
        <time_frame>Over the entire 4 year follow up period (17 - 20 years)</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>HBV 5 Group</title>
            <description>neonates born to Hepatitis B surface antigen negative (HBsAg-) and Hepatitis B e antigen negative (HBeAg-) mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)</description>
          </group>
          <group group_id="O2">
            <title>HBV 2 Group</title>
            <description>neonates born to Hepatitis B surface antigen positive (HBsAg+) and Hepatitis B e antigen positive (HBeAg+) mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)</description>
          </group>
          <group group_id="O3">
            <title>HBV 1 Group</title>
            <description>neonates born to HBsAg+ and HBeAg+ mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)</description>
          </group>
          <group group_id="O4">
            <title>HBV 4 Group</title>
            <description>neonates born to HBsAg+ and HBeAg- mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)</description>
          </group>
          <group group_id="O5">
            <title>HBV 3 Group</title>
            <description>neonates born to HBsAg+ and HBeAg- mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)</description>
          </group>
          <group group_id="O6">
            <title>HBV 6 Group</title>
            <description>neonates born to HBsAg- and HBeAg- mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="20"/>
                  <measurement group_id="O3" value="17"/>
                  <measurement group_id="O4" value="23"/>
                  <measurement group_id="O5" value="29"/>
                  <measurement group_id="O6" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Clinical Review for Hepatitis B Infection Status</title>
            <description>Chronic hepatitis B (HB) carrier is defined as positive for anti-HBc AND HBsAg at two or more consecutive time points</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Chronic HB carriers</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Chronic HB carriers among primary study responders</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="0"/>
                  <measurement group_id="O6" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
